Pyxis Oncology, Inc.
NASDAQ:PYXS
Overview | Financials
Company Name | Pyxis Oncology, Inc. |
Symbol | PYXS |
Currency | USD |
Price | 4.62 |
Market Cap | 274,533,997 |
Dividend Yield | 0% |
52-week-range | 1.35 - 6.85 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Lara S. Sullivan M.D., MBA |
Website | https://www.pyxisoncology.com |
An error occurred while fetching data.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC),
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD